title: Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
abstract: BACKGROUND
  Delayed elimination of methotrexate associated with serious side-effects has been attributed to the co-administration of benzimidazole proton pump inhibitors.
  
  
  METHODS
  We have retrospectively analyzed the causes of delayed methotrexate elimination in patients who had received the rescue agent glucarpidase to evaluate the potential implication of benzimidazoles.
  
  
  RESULTS
  Between 2002 and 2008, six patients (mean age: 30 years; range: 4-74 years) were treated with glucarpidase. Delayed elimination associated with impaired renal function occured after the first cycle except in 2 patients (2nd and 8th administration of high-dose methotrexate). The possible causes of delayed elimination identified were: insufficient hydration (n=1) and drug-drug interactions (n=5). The potential drug-drug interactions included the co-administration of piperacillin/tazobactam (n=1) and proton pump inhibitors (omeprazole, n=3; esomeprazole, n=2). Impaired elimination of methotrexate was not observed either in the 3 patients who were treated further or during the previous cycles of the 2 pretreated patients in relation to the absence of co-prescription of proton pump inhibitors.
  
  
  CONCLUSIONS
  In line with the recent literature and given the prohibitive cost of glucarpidase, we have advocated the cessation of proton pump inhibitors administration during methotrexate treatment.
authors.affiliation: Pharmacy, Hôpital Hautepierre, avenue Molière, 67000 Strasbourg, France.
authors.forename: Raoul
authors.initials: R
authors.lastname: Santucci
authors.forename: Dominique
authors.initials: D
authors.lastname: Levêque
authors.forename: Véronique
authors.initials: V
authors.lastname: Kemmel
authors.forename: Patrick
authors.initials: P
authors.lastname: Lutz
authors.forename: Anne-Cécile
authors.initials: AC
authors.lastname: Gérout
authors.forename: Aurélia
authors.initials: A
authors.lastname: N'guyen
authors.forename: Aurélie
authors.initials: A
authors.lastname: Lescoute
authors.forename: Francis
authors.initials: F
authors.lastname: Schneider
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bergerat
authors.forename: Raoul
authors.initials: R
authors.lastname: Herbrecht
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000506:poisoning*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004347:Drug Interactions; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000378:metabolism; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000506:poisoning*; D008875:Middle Aged; D009447:Neuroblastoma / Q000188:drug therapy / Q000378:metabolism; D012516:Osteosarcoma / Q000188:drug therapy / Q000378:metabolism; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D012189:Retrospective Studies; D055815:Young Adult; D011623:gamma-Glutamyl Hydrolase / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D011623:gamma-Glutamyl Hydrolase; D008727:Methotrexate